User profiles for Dean Fergusson
Dean A FergussonSenior Scientist, Ottawa Hospital Research Institute Verified email at ohri.ca Cited by 56752 |
Anti‐fibrinolytic use for minimising perioperative allogeneic blood transfusion
…, D O'Connell, BJ Stokes, DA Fergusson… - Cochrane database …, 2011 - cochranelibrary.com
Background Concerns regarding the safety of transfused blood have led to the development
of a range of interventions to minimise blood loss during major surgery. Anti‐fibrinolytic …
of a range of interventions to minimise blood loss during major surgery. Anti‐fibrinolytic …
Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
…, N Roubinian, DA Fergusson… - Cochrane database …, 2016 - cochranelibrary.com
Background There is considerable uncertainty regarding the optimal haemoglobin threshold
for the use of red blood cell (RBC) transfusions in anaemic patients. Blood is a scarce …
for the use of red blood cell (RBC) transfusions in anaemic patients. Blood is a scarce …
Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research
…, E Ezer, M Fabricius, J Feng, D Fergusson… - The Lancet …, 2017 - thelancet.com
A concerted effort to tackle the global health problem posed by traumatic brain injury (TBI) is
long overdue. TBI is a public health challenge of vast, but insufficiently recognised, …
long overdue. TBI is a public health challenge of vast, but insufficiently recognised, …
[HTML][HTML] A comparison of aprotinin and lysine analogues in high-risk cardiac surgery
DA Fergusson, PC Hébert, CD Mazer… - … England Journal of …, 2008 - Mass Medical Soc
Background Antifibrinolytic agents are commonly used during cardiac surgery to minimize
bleeding and to reduce exposure to blood products. We sought to determine whether …
bleeding and to reduce exposure to blood products. We sought to determine whether …
[HTML][HTML] Safe ty of cell therapy with mesenchymal stromal cells (safecell): A systematic review and meta-analysis of clinical trials
Background Mesenchymal stromal cells (MSCs, “adult stem cells”) have been widely used
experimentally in a variety of clinical contexts. There is interest in using these cells in critical …
experimentally in a variety of clinical contexts. There is interest in using these cells in critical …
Tiotropium in combination with placebo, salmeterol, or fluticasone–salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial
SD Aaron, KL Vandemheen, D Fergusson… - Annals of internal …, 2007 - acpjournals.org
Background: Treatment of moderate or severe chronic obstructive pulmonary disease (COPD)
with combinations of inhaled corticosteroids, long-acting β-agonists, and long-acting …
with combinations of inhaled corticosteroids, long-acting β-agonists, and long-acting …
Clinical consequences of red cell storage in the critically ill
Red cell (RBC) transfusions are a potentially life‐saving therapy employed during the care
of many critically ill patients to replace losses in hemoglobin to maintain oxygen delivery to …
of many critically ill patients to replace losses in hemoglobin to maintain oxygen delivery to …
Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and …
…, BL Houston, L McIntyre, JC Marshall, DA Fergusson - Jama, 2013 - jamanetwork.com
Importance Hydroxyethyl starch is commonly used for volume resuscitation yet has been
associated with serious adverse events, including acute kidney injury and death. Clinical trials …
associated with serious adverse events, including acute kidney injury and death. Clinical trials …
Cell salvage for minimising perioperative allogeneic blood transfusion
…, D O'Connell, T Brown, DA Fergusson - Cochrane database …, 2010 - cochranelibrary.com
Background Concerns regarding the safety of transfused blood have prompted reconsideration
of the use of allogeneic (from an unrelated donor) red blood cell (RBC) transfusion, and …
of the use of allogeneic (from an unrelated donor) red blood cell (RBC) transfusion, and …
[HTML][HTML] Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
…, DV Devine, J Dumaresq, DA Fergusson… - Nature medicine, 2021 - nature.com
The efficacy of convalescent plasma for coronavirus disease 2019 (COVID-19) is unclear.
Although most randomized controlled trials have shown negative results, uncontrolled studies …
Although most randomized controlled trials have shown negative results, uncontrolled studies …